oru.sePublikasjoner
Endre søk
Begrens søket
1 - 18 of 18
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Treff pr side
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
Merk
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1.
    Adams, A.
    et al.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Kalla, R.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Vatn, S.
    Institute of Clinical Medicine, EpiGen, University of Oslo, Oslo, Norway.
    Bonfiglio, F.
    BioCruces Health Research Institue, Bilbao, Spain.
    Nimmo, E.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Kennedy, N.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Ventham, N.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Vatn, M.
    Institute of Clinical Medicine, EpiGen, University of Oslo, Oslo, Norway.
    Ricanek, P.
    Department of Gastroenterology, Akershus University, Akershus, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Söderholm, J.
    Department of Surgery, Linköping University Hospital, Linköping, Sweden;.
    Pierik, M.
    Department of Gastroenterology and Hepatology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands.
    Törkvist, L.
    Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
    Gomollon, F.
    University Hospital Clinic Lozano Blesa, Zaragoza, Spain.
    Gut, I.
    CNAG-CRG Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
    Jahnsen, J.
    Institute of Clinical Medicine, EpiGen, University of Oslo, Oslo, Norway.
    Satsangi, J.
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
    Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character2017Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, nr Suppl. 1, s. S108-S108Artikkel i tidsskrift (Fagfellevurdert)
  • 2.
    Andersson, Erik
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Kruse, Robert
    Örebro universitet, Institutionen för medicinska vetenskaper.
    D'Amato, M.
    Department of Medicine, Karolinska Institutet Solna, Stockholm, Sweden.
    Repsilber, Dirk
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Inflammatory biomarkers in serum discriminate Crohn's disease and ulcerative colitis from healthy controls2016Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, nr Suppl. 1, s. S86-S87Artikkel i tidsskrift (Annet vitenskapelig)
  • 3.
    Andersson, Erik
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Kruse, Robert
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Neumann, Gunter
    School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    D'Amato, Mauro
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; BioDonostia Health Research Institute, San Sebastian, Spain; IKERBASQUE Basque Foundation for Science, Bilbao, Spain.
    Repsilber, Dirk
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles2017Inngår i: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 12, nr 10, artikkel-id e0186142Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objective: Genetic and immunological data indicate that inflammatory bowel disease (IBD) are characterized by specific inflammatory protein profiles. However, the serum proteome of IBD is still to be defined. We aimed to characterize the inflammatory serum protein profiles of Crohn's disease (CD) and ulcerative colitis (UC), using the novel proximity extension assay.

    Methods: A panel of 91 inflammatory proteins were quantified in a discovery cohort of CD (n = 54), UC patients (n = 54), and healthy controls (HCs; n = 54). We performed univariate analyses by t-test, with false discovery rate correction. A sparse partial least-squares (sPLS) approach was used to identify additional discriminative proteins. The results were validated in a replication cohort.

    Results: By univariate analysis, 17 proteins were identified with significantly different abundances in CD and HCs, and 12 when comparing UC and HCs. Additionally, 64 and 45 discriminant candidate proteins, respectively, were identified with the multivariate approach. Correspondingly, significant cross-validation error rates of 0.12 and 0.19 were observed in the discovery cohort. Only FGF-19 was identified from univariate comparisons of CD and UC, but 37 additional discriminant candidates were identified using the multivariate approach. The observed cross-validation error rate for CD vs. UC remained significant when restricting the analyses to patients in clinical remission. Using univariate comparisons, 16 of 17 CD-associated proteins and 8 of 12 UC-associated proteins were validated in the replication cohort. The area under the curve for CD and UC was 0.96 and 0.92, respectively, when the sPLS model from the discovery cohort was applied to the replication cohort.

    Conclusions: By using the novel PEA method and a panel of inflammatory proteins, we identified proteins with significantly different quantities in CD patients and UC patients compared to HCs. Our data highlight the potential of the serum IBD proteome as a source for identification of future diagnostic biomarkers.

  • 4.
    Bergemalm, Daniel
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Kruse, Robert
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län.
    Sapnara, Maria
    Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Hultgren Hörnquist, Elisabeth
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD2017Inngår i: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 12, nr 3, artikkel-id e0174275Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: The identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms.

    Methods: Fecal samples were collected at onset of inflammation in Galphai2(-/-) mice, a well-described spontaneous model of chronic colitis, and from healthy littermates. The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were then validated in a new cohort of mice.

    Results: As a potential top marker of disease, peptidase D was found at a higher ratio in Galphai24mouse feces relative to controls (fold change 27; p = 0.019). Other proteins found to be enriched in Gai2(-/-) mice were mainly pancreatic proteases, and proteins from plasma and blood cells. A tendency of increased calprotectin, subunit S100-A8, was also observed (fold change 21; p = 0.058). Proteases are potential activators of inflammation in the gastrointestinal tract through their interaction with the proteinase-activated receptor 2 (PAR2). Accordingly, the level of PAR2 was found to be elevated in both the colon and the pancreas of Galphai24- mice at different stages of disease.

    Conclusions: These findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis. The elevated levels of fecal proteases may be involved in the pathogenesis of colitis and contribute to the clinical phenotype, possibly by activation of intestinal PAR2.

  • 5.
    Eriksson, Carl
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Vigren, L.
    Dept Med, Div Gastroenterol, Hosp Trelleborg, Trelleborg, Sweden.
    Nilsson, L.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Visuri, Isabella
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden; Dept Clin & Expt Med, Linköping, Sweden.
    Udumyan, Ruzan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Almer, S.
    Dept Med, Gastrocentrum, Karolinska Inst, Stockholm, Sweden.
    Seddighzadeh, M.
    Merck Sharp & Dohme Ltd, Stockholm, Sweden.
    Hertervig, E.
    Dept Gastroenterol, Skane Univ Hosp, Lund, Sweden.
    Karlen, P.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Strid, H.
    Dept Internal Med, Södra Älvsborgs Hosp, Borås, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG2018Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S409-S410Artikkel i tidsskrift (Annet vitenskapelig)
  • 6.
    Eriksson, Carl
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Faculty of Medicine and Health, Örebro university, Örebro, Sweden.
    Marsal, Jan
    Immunology Section, Lund University, Lund, Sweden; Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Vigren, Lina
    Department of Internal Medicine, Ystad Hospital, Ystad, Sweden.
    Björk, Jan
    Department of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institutet Solna, Stockholm, Sweden.
    Eberhardson, Michael
    Department of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institutet Solna, Stockholm, Sweden.
    Karling, Pontus
    Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
    Söderman, Charlotte
    Department of Internal Medicine, St Göran Hospital, Stockholm, Sweden.
    Myrelid, Pär
    Department of Clinical and Experimental Medicine, Linköping University and Department of Surgery, Linköping University Hospital, Linköping, Sweden.
    Cao, Yang
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
    Sjöberg, Daniel
    Center for Clinical Research Dalarna, Uppsala University, Falun, Sweden.
    Thörn, Mari
    Department of Medical Sciences, Section of Gastroenterology and Hepatology, Uppsala University, Uppsala, Sweden.
    Karlén, Per
    Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden.
    Hertervig, Erik
    Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
    Strid, Hans
    Department of Internal Medicine, Södra Älvsborgs Sjukhus, Borås, Sweden.
    Ludvigsson, Jonas F.
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.
    Almer, Sven
    Department of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institutet Solna, Stockholm, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)2017Inngår i: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 52, nr 6-7, s. 722-729Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objectives: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness.

    Materials and methods: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted. Clinical remission was defined as Patient Harvey Bradshaw index<5 in Crohn's disease (CD) and Patient Simple Clinical Colitis Activity index<3 in ulcerative colitis (UC).

    Results: Two-hundred forty-six patients (147CD, 92 UC and 7 IBD-Unclassified) were included. On study entry, 86% had failed TNF-antagonist and 48% of the CD patients had undergone1 surgical resection. After a median follow-up of 17 (IQR: 14-20) months, 142 (58%) patients remained on vedolizumab. In total, 54% of the CD- and 64% of the UC patients were in clinical remission at the end of follow-up, with the clinical activity decreasing (p<.0001 in both groups). Faecal-calprotectin decreased in CD (p<.0001) and in UC (p=.001), whereas CRP decreased in CD (p=.002) but not in UC (p=.11). Previous anti-TNF exposure (adjusted HR: 4.03; 95% CI: 0.96-16.75) and elevated CRP at baseline (adjusted HR: 2.22; 95% CI: 1.10-4.35) seemed to be associated with discontinuation because of lack of response. Female sex was associated with termination because of intolerance (adjusted HR: 2.75; 95% CI: 1.16-6.48).

    Conclusion: Vedolizumab-treated patients represent a treatment-refractory group. A long-term effect can be achieved, even beyond 1 year of treatment.

  • 7.
    Eriksson, Carl
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Rundquist, Sara
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Lykiardopoulos, V.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden.
    Karlen, P.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Grip, O.
    Dept Gastroenterol, Skane Univ Hosp, Malmö, Sweden.
    Söderman, C.
    Dept Internal Med, St Goran Hosp, Stockholm, Sweden.
    Almer, S.
    Dept Med, Karolinska Inst, Stockholm, Sweden.
    Hertervig, E.
    Dept Gastroenterol, Skåne Univ Hosp, Lund, Sweden.
    Gunnarsson, J.
    Dept Internal Med, Kungsbacka Hosp, Kungsbacka, Sweden.
    Malmgren, C.
    Takeda Pharma AB, Solna, Sweden.
    Delin, J.
    Dept Gastroenterol, Ersta Hosp, Stockholm, Sweden.
    Strid, H.
    Dept Internal Med, Södra Älvsborgs Hosp, Borås, Sweden.
    Sjöberg, M.
    Dept Internal Med, Skaraborgs Hosp, Lidköping, Sweden.
    Öberg, D.
    Dept Internal Med, Sunderby Hosp, Sunderbyn, Sweden.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Udumyan, Ruzan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ, Linöping, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD)2018Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S494-S495Artikkel i tidsskrift (Annet vitenskapelig)
  • 8.
    Eriksson, Carl
    et al.
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Rundquist, Sara
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Lykiardopoulos, V.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden.
    Karlen, P.
    Dept Internal Med, Danderyd Hosp, Stockholm, Sweden.
    Grip, O.
    Dept Gastroenterol, Skåne Univ Hosp, Malmö, Sweden.
    Söderman, C.
    Dept Internal Med, St Göran Hosp, Stockholm, Sweden.
    Almer, S.
    Dept Med, Karolinska Inst, Stockholm, Sweden.
    Hertervig, E.
    Dept Gastroenterol, Skåne Univ Hosp, Lund, Sweden.
    Gunnarsson, J.
    Dept Internal Med, Kungsbacka Hosp, Kungsbacka, Sweden.
    Malmgren, C.
    Takeda Pharma AB, Solna, Sweden.
    Delin, J.
    Dept Gastroenterol, Ersta Hosp, Stockholm, Sweden.
    Strid, H.
    Dept Internal Med, Södra Älvsborgs Hosp, Borås, Sweden.
    Sjöberg, M.
    Dept Internal Med, Skaraborgs Hosp, Lidköping, Sweden.
    Öberg, D.
    Dept Internal Med, Sunderby Hosp, Sunderbyn, Sweden.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Udumyan, Ruzan
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ, Linköping, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)2018Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S382-S383Artikkel i tidsskrift (Annet vitenskapelig)
  • 9. Kalla, R.
    et al.
    Adams, A. T.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Vatn, S.
    Gastroenterology, Akershus University, Lorenskog, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Ricanek, P.
    Gastroenterology, Institute of Clinical Medicine, Oslo, Norway.
    Lindstrom, J. C.
    Gastroenterology, Akershus University, Lorenskog, Norway.
    Ocklind, A.
    Olink Proteomics, Uppsala, Sweden.
    Nordberg, N.
    Olink Proteomics, Uppsala, Sweden.
    Kennedy, N. A.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Ventham, N.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Vatn, M. H.
    Gastroenterology, Institute of Clinical Medicine, Oslo, Norway.
    Söderholm, J. D.
    Surgery, Linköping University, Linköping, Sweden.
    Pierik, M.
    Gastroenterology, Maastricht University Medical centre, Maastricht, Netherlands.
    Torkvist, L.
    Clinical Science, Karolinska Instituet, Karolinska, Sweden.
    Gomollon, F.
    Gastroenterology, HCU “Lozano Blesa” , Zaragosa, Spain.
    Jahnsen, J.
    Gastroenterology, Akershus University, Lorenskog, Norway.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Satsangi, J.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: ibd character study2017Inngår i: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 66, nr Suppl. 2, s. A202-A203, artikkel-id AODTH-008Artikkel i tidsskrift (Annet vitenskapelig)
  • 10. Kalla, R.
    et al.
    Adams, A. T.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Vatn, S.
    Gastroenterology, Akershus University, Lorenskog, Norway.
    Bonfiglio, F.
    Gastroenterology, Biocruces Health Research Institute, Bilbao, Spain.
    Nimmo, E. R.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Kennedy, N. A.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Ventham, N.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Vatn, M. H.
    Gastroenterology, Institute of Clinical Medicine, Oslo, Norway.
    Ricanek, P.
    Gastroenterology, Institute of Clinical Medicine, Oslo, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Gastroenterology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden.
    Söderholm, J. D.
    Surgery, Linköping Univeristy, Linköping, Sweden.
    Pierik, M.
    Gastroenterology, Maastricht University Medical centre, Maastricht, Netherlands.
    Torkvist, L.
    Clinical Science, Karolinska Instituet, Karolinska, Sweden.
    Gomollon, F.
    Gastroenterology, HCU “Lozano Blesa”, Zaragosa, Spain.
    Gut, I.
    Centre for Genomic Regulation, CNAG-CRG, Barcelona, Spain.
    Jahnsen, J.
    Gastroenterology, Akershus University, Lorenskog, Norway.
    Satsangi, J.
    Gastroenterology, University of Edinburgh, Edinburgh, UK.
    Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character2017Inngår i: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 66, nr Suppl. 2, s. A24-A25, artikkel-id OC-047Artikkel i tidsskrift (Annet vitenskapelig)
  • 11.
    Kalla, R.
    et al.
    Gastroenterology, University of Edinburgh, Edinburgh, United Kingdom.
    Adams, A.
    Gastroenterology, University of Edinburgh, Edinburgh, United Kingdom.
    Vatn, S.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterolog, Örebro University Hospital, Örebro, Sweden.
    Ricanek, P.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Lindström, J.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
    Ocklind, A.
    Olink Proteomics, Uppsala, Sweden.
    Nordberg, N.
    Olink Proteomics, Uppsala, Sweden.
    Kennedy, N.
    Gastroenterology, University of Edinburgh, Edinburgh, United Kingdom.
    Ventham, N.
    Gastroenterology, University of Edinburgh, Edinburgh, United Kingdom.
    Vatn, M.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Söderholm, J.
    Gastroenterology, Linköping University, Linköping, Sweden.
    Pierik, M.
    Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands.
    Törkvist, L.
    Department of Clinical Science, Intervention and Technology, Karolinska Instituet, Karolinska Institute, Stockholm, Sweden.
    Gomollon, F.
    Instituto de Investigación Sanitaria Aragón (IIS Aragón), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Hospital Clínico Universitario (HCU) “Lozano Blesa”, Zaragosa, Spain.
    Jahnsen, J.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden.
    Satsangi, J.
    Gastroenterology, University of Edinburgh, Edinburgh, United Kingdom.
    Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study2017Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, nr Suppl. 1, s. S13-S13Artikkel i tidsskrift (Fagfellevurdert)
  • 12.
    Kalla, R.
    et al.
    Gastrointestinal Unit, Univ Edinburgh, Edinburgh, UK.
    Kennedy, N.
    Gastrointestinal Unit, Univ Edinburgh, Edinburgh, UK.
    Hjelm, F.
    Olink Bioscience AB, Uppsala, Sweden.
    Modig, E.
    Olink Bioscience AB, Uppsala, Sweden.
    Sundell, M.
    Olink Bioscience AB, Uppsala, Sweden.
    Andreassen, B.
    Inst Clin Med, Univ Oslo, Oslo, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för hälsovetenskap och medicin.
    Ricanek, P.
    Dept Gastroenterol, Akershus Univ Hosp, Lorenskog, Norway.
    Söderholm, J.
    Gastroenterol, Linköping Univ, Linköping, Sweden.
    Vatn, M.
    Inst Clin Med, Univ Oslo, Oslo, Norway.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för läkarutbildning.
    Gullberg, M.
    Olink, Biosci, Uppsala, Sweden.
    Satsangi, J.
    Gastrointestinal Unit, Univ Edinburgh, Edinburgh, UK.
    Proximity Extension Assay technology identifies novel serum biomarkers for predicting Inflammatory Bowel Disease: IBD Character Consortium2015Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 9, s. S146-S147Artikkel i tidsskrift (Annet vitenskapelig)
  • 13.
    Kalla, R.
    et al.
    Gastroenterol, Univ Edinburgh, Edinburgh, UK.
    Ocklind, A.
    Olink Bioscience AB, Uppsala, Sweden.
    Petren, C.
    Olink Bioscience AB, Uppsala, Sweden.
    Nordberg, N.
    Olink Bioscience AB, Uppsala, Sweden.
    Kennedy, N.
    Gastroenterol, Univ Edinburgh, Edinburgh, UK.
    Ventham, N.
    Gastroenterol, Univ Edinburgh, Edinburgh, UK.
    Pettersson, E.
    Olink Bioscience AB, Uppsala, Sweden.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Lindstrom, J.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway.
    Vatn, S.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway.
    Hjortswang, H.
    Dept Gastroenterol, Linköping Univ Hosp, Linköping, Sweden.
    Nimmo, E.
    Univ Edinburgh, Gastroenterol, Edinburgh, UK..
    Drummond, H.
    Univ Edinburgh, Gastroenterol, Edinburgh, UK.
    Ricanek, P.
    Deprtment Gastroenterol, Akershus Univ Hosp, Lorenskog, Norway..
    Dahl, F.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway..
    Wilson, D.
    Gastroenterol, Univ Edinburgh, Edinburgh, UK.
    Jahnsen, J.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway.
    Gomollon, F.
    Gastroenterol, Univ Zaragosa, Zaragoza, Spain.
    Pierik, M.
    Dept Gastroenterol & Hepatol, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands.
    Soderholm, J.
    Dept Surg, Linköping Univ Hosp, Linköping, Sweden.
    Vatn, M.
    Dept Gastroenterol, Oslo Univ Hosp, Oslo, Norway.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Satsangi, J.
    Gastroenterol, Univ Edinburgh, Edinburgh, UK.
    Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character Consortium2016Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 10, nr Suppl. 1, s. S82-S82Artikkel i tidsskrift (Annet vitenskapelig)
  • 14.
    Koskela von Sydow, Anita
    et al.
    Örebro universitet, Institutionen för hälsovetenskaper.
    Janbaz, Chris
    Department of Plastic and Reconstructive Surgery Clinic, School of Medical Science, Örebro University SE 70182, Örebro, Sweden.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för hälsovetenskaper. Department of Internal Medicine, Division of Gastroenterology.
    Ivarsson, Mikael
    Örebro universitet, Institutionen för hälsovetenskaper.
    IL-1α counteracts TGF-β regulated protein expression in human dermal fibroblastsManuskript (preprint) (Annet vitenskapelig)
  • 15.
    Ricanek, P.
    et al.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
    Rahul, K.
    University of Edinburgh, Edinburgh, United Kingdom.
    Ber, Y.
    Hospital Clinico Universitario, Zaragoza, Spain.
    Vatn, S.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Finnby, L.
    Genetic Analysis AS, Oslo, Norway.
    Lindahl, T.
    Genetic Analysis AS, Oslo, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län.
    Carstens, Adam
    Örebro universitet, Institutionen för medicinska vetenskaper.
    Söderholm, J.
    Linköping University, Linköping, Sweden.
    Jahnsen, J.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Gomollon, F.
    Hospital Clinico Universitario, Zaragoza, Spain.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län.
    Satsangi, J.
    University of Edinburgh, Edinburgh, United Kingdom.
    Casen, C.
    Genetic Analysis AS, Oslo, Norway.
    Vatn, M. H.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease2017Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, nr Suppl. 1, s. S483-S484Artikkel i tidsskrift (Fagfellevurdert)
  • 16.
    Vatn, S.
    et al.
    Akershus University Hospital, Akershus, Norway.
    Karlsson, M. C.
    Genetic Analysis AS, Oslo, Norway.
    Carstens, Adam
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Ersta Hospital, Stockholm, Sweden.
    Detlie, T. E.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Ricanek, P.
    Akershus University Hospital, Akershus, Norway.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology.
    Lindquist, C. M.
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Jahnsen, J.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology.
    Casen, C.
    Genetic Analysis AS, Oslo, Norway.
    Vatn, M. H.
    Oslo University, Oslo, Norway.
    Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation2018Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S555-S555Artikkel i tidsskrift (Annet vitenskapelig)
  • 17.
    Vatn, S.
    et al.
    Akershus University Hospital, Akershus, Norway.
    Karlsson, M. C.
    Genetic Analysis AS, Oslo, Norway.
    Carstens, Adam
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Ersta Hospital, Stockholm, Sweden.
    Detlie, T. E.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Ricanek, P.
    Akershus University Hospital, Akershus, Norway.
    Lindquist, C. M.
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology.
    Jahnsen, J.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology.
    Casen, C.
    Genetic Analysis AS, Oslo, Norway.
    Vatn, M. H.
    Oslo University, Oslo, Norway.
    Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation2018Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S557-S557Artikkel i tidsskrift (Annet vitenskapelig)
  • 18.
    Zammit, Stefania Chetcuti
    et al.
    Mater Dei Hospital, LImsida, Malta.
    Ellul, Pierre
    Mater Dei Hospital, L Msida, Malta.
    Girardin, Giulia
    University of Padua, Padua, Italy.
    Valpiani, Daniela
    Ospedale "G.B. Morgagni L. Pierantoni", Forlì, Italy.
    Nielsen, Kári R.
    The National Hospital of the Faroe Islands, Torshavn, Faroe Islands.
    Olsen, Jóngerð
    The National Hospital of the Faroe Islands, Torshavn, Faroe Islands.
    Goldis, Adrian
    University of Medicine ‘Victor Babes’, Timisoara, Romania.
    Lazar, Daniela
    University of Medicine ‘Victor Babes’, Timisoara, Romania.
    Shonová, Olga
    Hospital Budweis, South Bohemia, Czech Republic.
    Nováková, Marie
    Hospital Budweis, South Bohemia, Czech Republic.
    Sebastian, Shaji
    IBD Unit, Hull and East Yorkshire NHS Trust, Kingston upon Hull, England.
    Whitehead, Emma
    IBD Unit, Hull and East Yorkshire NHS Trust, Kingston upon Hull, England.
    Carmona, Amalia
    Hospital Povisa, Vigo, Spain.
    Martinez-Cadilla, Jesus
    Instituto de Investigación Biomédica Galicia Sur. Estrutura Organizativa de Xestión Integrada de Vigo, Spain.
    Dahlerup, Jens F.
    Aarhus University Hospital, Aarhus, Denmark.
    Kievit, Adriana L. H.
    Herning, Denmark.
    Thorsgaard, Niels
    Herning, Denmark.
    Katsanos, Konstantinos H.
    Medical School and University Hospital of Ioannina, Ioannina, Greece.
    Christodoulou, Dimitrios K.
    Medical School and University Hospital of Ioannina, Ioannina, Greece.
    Magro, Fernando
    Hospital São João, Porto, Portugal; Institute of Pharmacology and Therapeutics Faculty of Medicine of the University of Porto, Porto, Portugal.
    Salupere, Riina
    Tartu University Hospital, University of Tartu, Tartu, Estonia.
    Pedersen, Natalia
    Slagelse Hospital, Slagelse, Denmark.
    Kjeldsen, Jens
    Odense University Hospital, Odense C, Denmark.
    Carlsen, Katrine
    Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
    Ioannis, Kaimaklioti
    Private Practice, Nicosia, Cyprus.
    Bergemalm, Daniel
    Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Gastroenterology.
    Halfvarson, Jonas
    Örebro universitet, Institutionen för medicinska vetenskaper. Department of Gastroenterology.
    Duricova, Dana
    IBD Clinical and Research Centre Iscare, Prague, Czech Republic.
    Bortlik, Martin
    IBD Clinical and Research Centre Iscare, Prague, Czech Republic.
    Collin, Pekka
    Tampere University Hospital, Tampere, Finland.
    Oksanen, Pia
    Tampere University Hospital, Tampere, Finland.
    Kiudelis, Gediminas
    Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Kupcinskas, Limas
    Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
    Kudsk, Karen
    Viborg Regional Hospital, Viborg, Denmark.
    Andersen, Vibeke
    IRS-Center Sonderjylland, Hospital of Southern Jutland, Aabenraa, Denmark.
    O'Morain, Colm
    Adelaide and Meath Hospital, TCD, Dublin, Ireland.
    Bailey, Yvonne
    Adelaide and Meath Hospital, TCD, Dublin, Ireland.
    Doron, Schwartz
    Soroka Medical Centre, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
    Shmuel, Odes
    Soroka Medical Centre, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
    Almer, Sven
    Karolinska Institutet, Solna, Sweden; Karolinska University Hospital, Stockholm, Sweden.
    Arebi, Naila
    IBD Department St Mark’s Hospital, London, UK.
    Misra, Ravi
    IBD Department St Mark’s Hospital, London, UK.
    Čuković-Čavka, Silvija
    University Hospital Center Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia.
    Brinar, Marko
    University Hospital Center Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia.
    Munkholm, Pia
    North Zealand University Hospital, Roskilde, Denmark.
    Vegh, Zsuzsanna
    Semmelweis University, Budapest, Hungary.
    Burisch, Johan
    North Zealand University Hospital, Roskilde, Denmark.
    Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study2018Inngår i: European Journal of Gastroenterology and Hepathology, ISSN 0954-691X, E-ISSN 1473-5687, Vol. 30, nr 11, s. 1297-1303Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Serum vitamin D level is commonly low in patients with inflammatory bowel disease (IBD). Although there is a growing body of evidence that links low vitamin D level to certain aspects of IBD such as disease activity and quality of life, data on its prevalence and how it varies across disease phenotype, smoking status and treatment groups are still missing.

    MATERIALS AND METHODS: Patients diagnosed with IBD between 2010 and 2011 were recruited. Demographic data and serum vitamin D levels were collected. Variance of vitamin D level was then assessed across different treatment groups, disease phenotype, disease activity and quality of life scores.

    RESULTS: A total of 238 (55.9% male) patients were included. Overall, 79% of the patients had either insufficient or deficient levels of vitamin D at diagnosis. Patients needing corticosteroid treatment at 1 year had significantly lower vitamin D levels at diagnosis (median 36.0 nmol/l) (P=0.035). Harvey-Bradshaw Index (P=0.0001) and Simple Clinical Colitis Activity Index scores (P=0.0001) were significantly lower in patients with higher vitamin D level. Serum vitamin D level correlated significantly with SIBQ score (P=0.0001) and with multiple components of SF12. Smokers at diagnosis had the lowest vitamin D levels (vitamin D: 34 nmol/l; P=0.053).

    CONCLUSION: This study demonstrates the high prevalence of low vitamin D levels in treatment-naive European IBD populations. Furthermore, it demonstrates the presence of low vitamin D levels in patients with IBD who smoke.

1 - 18 of 18
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf